‹ Back
PNC-27
How it is taken
The schedule
| Route | No human route or schedule is established; the animal work used dosing into the abdominal cavity, and any use in a person belongs with an oncology team inside a supervised study |
|---|
There is no human route or schedule for this construct, because the work has not reached people and no one has established one. In the animal work it was given into the abdominal cavity of mice, daily, across about two weeks, and in cell work it is applied directly to cells in a dish. Any use in a person belongs with an oncology team inside a properly supervised study, which is also the only setting where it could be given safely and measured properly. If you want to pursue it, the route is to ask your cancer team what studies exist and whether you are eligible.
Your personal schedule is set after we review your survey.
Sources
Read the original sources
- PNC-28, a p53-derived peptide cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo (Abstract · checked 2026-10-13)
- Ex vivo efficacy of PNC-27 in the treatment of patient-derived epithelial ovarian cancer (Abstract · checked 2026-10-13)
- Poptosis or peptide-induced transmembrane pore formation: a novel way to kill cancer cells without affecting normal cells (Summary · checked 2026-10-13)